Compare BXMT & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BXMT | EWTX |
|---|---|---|
| Founded | 1966 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.5B |
| IPO Year | N/A | 2021 |
| Metric | BXMT | EWTX |
|---|---|---|
| Price | $20.59 | $23.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $20.25 | ★ $35.89 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 10-29-2025 | 11-06-2025 |
| Dividend Yield | ★ 9.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.62 | N/A |
| Revenue | ★ $393,335,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.51 | N/A |
| P/E Ratio | $32.87 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.51 | $10.60 |
| 52 Week High | $21.24 | $35.50 |
| Indicator | BXMT | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 74.50 | 62.93 |
| Support Level | $19.55 | $22.77 |
| Resistance Level | $20.67 | $25.00 |
| Average True Range (ATR) | 0.32 | 1.33 |
| MACD | 0.11 | -0.27 |
| Stochastic Oscillator | 98.43 | 44.20 |
Blackstone Mortgage Trust Inc is a real estate finance company involved in the origination and purchase of senior loans collateralized by commercial properties in North America, Europe, and Australia. The vast majority of the company's asset portfolio is comprised of floating rate loans secured by priority mortgages. These mortgages are mainly derived from office, hotel, and manufactured housing properties. A percentage of the collateralized real estate properties are located in New York, California, and the United Kingdom. Blackstone Mortgage Trust is managed by a subsidiary of The Blackstone Group and benefits from the market data provided by its parent company. Nearly all of Blackstone Mortgage Trust's revenue is generated in the form of interest income.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.